Patients with acute myeloid leukemia (AML) without complete remission (CR) or in first relapse (Rel1) can have extended leukemia control and survival after allogeneic hematopoietic cell transplantation (HCT). For patients in Rel1 or primary induction failure (PIF), transplantation versus treatment to achieve a second CR (CR2) and subsequent HCT might yield similar outcomes, but available comparative data are scarce. METHODS: Survival was analyzed in 4682 HCT recipients according to disease status: PIF (N 5 1440), Rel1 (failing 1 reinduction; N 5 1256), and CR2 (N 5 1986). RESULTS: Patient, disease, and transplantation characteristics were similar, except that patients in CR2 more often had performance scores of 90% to 100%, de novo AML, and longer CR1 duration. Adverse cytogenetics were more common in patients who experienced PIF. The 5-year survival rate adjusted for performance score, cytogenetic risk, and donor type for CR2 was 39% (95% confidence interval [CI], 37%-41%) compared with 18% (95% CI, 16%-20%) for HCT in Rel1 and 21% (95% CI, 19%-23%) in PIF (P < .0001). CONCLUSIONS: Although survival is superior for patients who undergo HCT in CR2, transplantation for selected patients in Rel1 or PIF may still be valuable. These data can guide decision making about additional salvage therapy versus prompt HCT for patients not in CR, but they also highlight that AML is intrinsically more treatable in patients who have favorable-risk cytogenetics, those with longer CR1 duration, and younger patients with better performance status.
INTRODUCTION
For patients with acute myeloid leukemia (AML) who fail to achieve complete remission (CR) or those in relapse after first CR (CR1), allogeneic hematopoietic cell transplantation (HCT) can produce leukemia control and extended survival. [1] [2] [3] [4] Some reports suggest that immediate transplantation, if an available donor can be quickly identified, is a best strategy for primary induction failure (PIF) or at first relapse (Rel1). [5] [6] [7] [8] Other data argue that additional therapy to achieve remission (whether it is a difficult-to-achieve CR1 or a second CR [CR2]) yields favorable outcomes and superior survival, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] noting that achieving CR may indicate intrinsically more responsive leukemia. Recognizing the limitation that our transplantation registry data cannot address outcomes for those who never undergo transplantation, we analyzed the comparative survival of patients who proceeded to allogeneic transplantation in PIF, Rel1, or CR2. These data can guide decision making about the utility of additional salvage therapy versus an alternative strategy of prompt transplantation therapy, even for patients who are not in CR. 
MATERIALS AND METHODS

Data Source
Data for this study were obtained from the Center for International Blood and Marrow Transplant Research (CIBMTR), a voluntary working group of more than 350 transplantation centers that report their consecutive transplantations to the CIBMTR. Data are collected on standardized data-collection forms pretransplantation; at 3, 6, and 12 months after transplantation; and annually thereafter until death or loss to follow-up. Compliance is ensured by on-site audits. Patients provided written informed consent, and the study was approved by the National Marrow Donor Program's Institutional Review Board.
Patients
Eligibility criteria included the following: patients aged 18 years with AML, in CR2 (n 5 1986), Rel1 (n 5 
Endpoints
The primary outcome was overall survival. Death from any cause was considered an event, and surviving patients were censored at last follow-up. Relapse was defined as morphologic recurrence of leukemic blasts in bone marrow or blood. Patients who underwent transplantation in Rel1 or PIF and relapsed within 3 months after transplantation were considered as having persistent leukemia.
Measures of pre-HCT residual disease (flow cytometry, fluorescence in situ hybridization, or molecular measures) were not consistently available for the patients in CR2 and were not analyzed. Nonrelapse mortality (NRM) was defined as death not attributed to relapse or persistent leukemia.
Statistical Methods
Demographic, leukemia, and transplantation characteristics were compared using the chi-square statistic for categorical variables. The probability of overall survival was calculated using the Kaplan-Meier estimator with 95% confidence limits derived from the standard error. The duration of survival was defined as the interval between the dates of transplantation and last contact. Multivariate analysis for overall mortality was performed using a Cox regression model. 20 Estimates of relapse and NRM were limited to patients who survived for at least 100 days after transplantation with documented CR (as a day 1100 landmark analysis). The subsequent incidences of relapse and NRM were calculated using the cumulative incidence estimator and considering competing risks. 21 The duration of post-transplantation remission or the time to death not attributed to relapse was defined as the interval between day 100 post-transplantation and the date of the event (relapse or death). Multivariate analyses for relapse and NRM were performed using the Fine and Gray regression model. 22 The factors tested in multivariate models included: disease status at HCT (CR2 vs Rel1 vs PIF) and the duration of CR1 for CR2 and Rel1, age (decade), time (in months from relapse to HCT for Rel1 and CR2), time from diagnosis to HCT (for PIF), the number of induction (or reinduction) cycles before HCT, performance score (90%-100% vs <90%), recipient cytomegalovirus (CMV) serostatus (positive vs negative), AML type (de novo vs secondary), white blood cell count at diagnosis (<30 vs 30-100 vs >100 3 10 Molecular data to define other high-risk subsets were not routinely available. Flt3 ligand mutation was positive in only 3% of each HCT cohort but was missing in the majority of patients. Adjusted probabilities for survival, relapse, and NRM were calculated considering the significant factors identified in final multivariate regression models and using left-truncation of the time from diagnosis (for PIF), or from relapse (for Rel1 or CR2) to HCT. All factors met the assumptions of proportionality, and there were no first-order interactions between disease status at transplantation and other factors that were retained in the final multivariate models. P values < .01 were considered statistically significant. The previously reported 15 CIBMTR score for HCT during relapse was also analyzed, but circulating and bone marrow blast counts were not reported for all patients; however, the analysis was performed using all available information. All analyses were performed with SAS version 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
Patient, disease, and transplantation characteristics are provided in Table 1 . Of the 4682 patients who met eligibility criteria, 1986 (36%) were in CR2, 1256 (27%) were in Rel1, and 30% were in PIF at the time of HCT. Seven percent of patients in CR2 and Rel1 had undergone a prior autologous HCT compared with 3% of patients in PIF. The median age in the 3 groups was 47, 49, and 52 years for the patients in CR2, Rel1, and PIF, respectively. Patient age, sex, and CMV serostatus were similar across the 3 groups, but patients who underwent transplantation in Rel1 or PIF were more likely to have Original Article performance scores <90%. HCT comorbidity index (HCT-CI) scores were available after 2008, and there were no differences between the groups, although there were differences in disease characteristics between the groups. Patients in CR2 were less likely to have secondary AML (therapy-related or evolved from myelodysplastic or myeloproliferative syndrome) or poor-risk cytogenetics compared with those in Rel1 or PIF. The duration of CR1 was <6 months for 50% of patients who underwent transplantation in Rel1 compared with 18% for those who underwent transplantation in CR2.
The duration of CR1 was >12 months for one-third of patients in CR2. Most transplantations in PIF (73%) occurred within 6 months from diagnosis. The median times from relapse to HCT for patients in Rel1 or CR2 were similar (2 and 4 months, respectively), and the numbers of cycles from relapse to HCT (or from diagnosis to HCT those in PIF) were also similar. There were no differences with regard to donor type between the groups; one-third of transplantations involved an HLAmatched sibling donor, 40% involved a suitably matched URD, and the remaining involved mismatched URDs. Only a few patients received nonsibling-related donors (including haploidentical donors). There were no differences in the intensity of transplantation-conditioning regimens and GVHD prophylaxis between the groups. Peripheral blood was the most common graft type. Approximately 80% of HCTs occurred in the United States. The median follow-up of 5 years for patients in CR2, 7 years for those in Rel1, and 5 years for those in PIF.
Overall Survival
At a median of 5 years of follow-up, 42% of patients in CR2, 17% of those in Rel1, and 20% of those in PIF remain alive. The unadjusted 2-year overall survival rate for patients who underwent transplantation in CR2, Rel1, and PIF was 50% (95% confidence interval [CI], 48%-52%), 27% (95% CI, 24%-29%), and 29% (95% CI, 27%-32%), respectively. The results of multivariate analysis are provided in Table 2 . Compared with patients who underwent transplantation in CR2, mortality risks were higher for those who underwent transplantation in Rel1 and PIF, and the duration of CR1, the bone marrow blast percentage (for PIF or Rel1), and the number of cycles of induction or reinduction before HCT did not influence mortality risks (data not shown). The outcome of transplantation in Rel1 versus PIF varied by CR1 duration for those who underwent transplantation in Rel1. Mortality risks were lower for patients who underwent transplantation in PIF than those who underwent transplantation in Rel1, but only if the CR1 duration was <6 months. Mortality risks were higher for patients who underwent transplantation in PIF if the CR1 duration was >months for Rel1 transplantations, but the mortality risks were similar in PIF and Rel1 transplantations when the CR1 duration was between 6 and 12 months. Other factors associated with overall mortality were age (50 years), poor performance scores (<90%), intermediate and poor cytogenetic risk, and mismatched-related or URD donors. The 5-year probability of overall survival after transplantation in CR2, Rel1, and PIF adjusted for age, performance score, cytogenetic risk, and donor type was 39% (95% CI, 37%-41%), 18% (95% CI, 16%-20%), and 21% (95% CI, 19%-23%), respectively ( Fig. 1) . Overall, there were 1159 deaths (58%) among patients who underwent transplantation in CR2, 1046 (83%) among those who underwent transplantation in Rel1, and 1145 (80%) among those who underwent transplantation in PIF. Recurrent or persistent leukemia was the most common cause of death, occurring in 485 of 1159 patients (42%) who underwent transplantation in CR2 and 567 of 1046 patients (54%) and 603 of 1145 patients (53%) who underwent transplantation in Rel1 and PIF, respectively. Other predominant causes of death included GVHD, infection, and organ failure.
Duval et al 15 previously reported a scoring system to predict relapse after myeloablative HCT for AML with active disease. Survival was inferior in patients who had a short initial remission, circulating blasts, donors other that HLA-identical siblings, performance scores <90%, and poor-risk cytogenetics. Although data were incomplete (circulating and bone marrow blasts were incompletely reported), a higher score was associated with inferior survival (Table 3) .
Relapse and NRM
Details of the population that was considered for analyses of relapse and NRM are provided in Table 4 . In this overall high-risk population, we noted that leukemia relapse was common within 100 days after HCT for patients who underwent transplantation in CR2 (n 5 221; 11%), and persistent disease before day 1100 was very common after HCT for patients who underwent transplantation in Rel1 (n 5 577; 46%) and in PIF (n 5 706; 49%). Thus, the analyses of relapse and NRM were limited to a landmark analysis that included only those patients who were alive and in CR at day 100 post-transplantation. Analysis of the factors associated with early death (before day 1100) or relapse/persistent leukemia indicated that disease status at transplantation (CR2 vs Rel1 vs PIF) was a significant risk factor for these early treatment failures. Adverse cytogenetics, a short CR1 duration, and receipt of GVHD prophylaxis also indicated higher risks of early treatment failure in all 3 cohorts; whereas transplantations in Rel1 and PIF, with lower performance scores, KPS, and year of HCT were also identified as important variables (data not shown).
The results from these post-day 1100 landmark multivariate analyses are provided in Table 5 . Compared with patients who underwent transplantation in CR2, the risk of post-day 1100 relapse was higher for those who underwent transplantation in Rel1, regardless of the CR2 duration. The risks of relapse also were higher in patients who underwent transplantation in PIF compared with those who underwent transplantation Rel1 with a CR1 duration >12 months, but not in those with shorter CR1 durations, for whom there were no differences in the risk of relapse after transplantation in either Rel1 or PIF. Compared with patients who underwent transplantation in CR2, the risks of NRM were higher for those who underwent transplantation in Rel1, regardless of CR1 duration. However, there were no significant differences in NRM risks after transplantations in CR2 or Rel1 compared with transplantations in PIF. Other factors associated with higher risks of relapse and NRM were age (50 years), poor performance scores (<90), intermediate and poor cytogenetic risk, and mismatched-related or URD donors.
The 5-year adjusted probabilities of relapse after transplantations in CR2, Rel1, and PIF adjusted for cytogenetic risk were 32% (95% CI, 29%-34%), 41% (95% CI, 36%-45%), and 40% (95% CI, 36%-44%), respectively (Fig.  2) . The corresponding probabilities for NRM were 23% (95% CI, 21%-25%), 28% (95% CI, 24%-32%), and 25% (95% CI, 21%-%29), respectively. (Fig. 3) .
DISCUSSION
Allogeneic transplantation in later stage AML can still yield long-term disease control and improved survival for sizable fractions of patients, but the current analysis strongly suggests that transplantation during CR2 is preferred over other approaches, including transplantation in Rel1 or PIF. This analysis has substantial and, to a large extent, unquantifiable selection bias because of the inclusion of only those patients who were deemed fit for HCT during relapse and who were referred to a center that accepted them for HCT. Nonetheless, the large numbers of patients, the multivariable regression adjustments, and the international experience likely represent valid outcomes for patients who undergo transplantation in these 3 clinical situations who are selected for HCT. The favorable outcomes after undergoing HCT in CR2 suggest that additional salvage therapy to induce remission for patients in PIF or Rel1 may yield a selected group who can have favorable post-transplantation outcomes and improved survival. Because attaining remission with additional therapy may only identify patients who have biologically less aggressive leukemia rather than rescuing the outcome of those with resistant disease, the risks and benefits of repetitive remission-induction attempts must be carefully considered, particularly as new agents and reinduction regimens are being developed and tested. Beyond disease status, outcomes were superior for those with intrinsically more treatable leukemia, including those who had favorable-risk cytogenetics and longer CR1 duration before relapse. In addition, patient characteristics, including age 50 years and good performance status (90% or 100%), also led to better survival. Transplantation was recognized as useful and yielded extended disease control in this broad array of patients with persistent, relapsed, or CR2 AML. This echoes reports from the earliest experience of transplantation, in which a fraction of patients with advanced AML could be salvaged using myeloablative conditioning and allografts. [7] [8] [9] [10] [11] [12] [13] [14] [15] Several decades ago, it was reported that untreated patients in Figure 2 . Among 100-day survivors in complete remission, the 5-year probability of relapse is illustrated according to disease status at transplantation adjusted for age, performance score, cytogenetic risk, and donor type. CR2 indicates second complete remission; Rel1, first relapse; PIF, primary induction failure. Figure 3 . Among-100 day survivors in complete remission, the 5-year probability of nonrelapse mortality is illustrated according to disease status at transplantation adjusted for age, performance score, cytogenetic risk, and donor type. CR2 indicates second complete remission; Rel1, first relapse; PIF, primary induction failure.
Rel1 and second remission had similar outcomes after allogeneic transplantation. 9, 10 In more recent series, including an earlier report from the CIBMTR, disease burden (manifest as bone marrow blast percentage or circulating blasts), high-risk phenotype (adverse cytogenetics), as well as age and performance status influenced the outcome of transplantation in patients with active disease. [11] [12] [13] [14] [15] Molecular or flow-cytometric measures of detectable disease, even for those in CR before HCT, 24 might further refine the prognosis after HCT, although such data were not available for the current analysis.
Limited, more recent experience incorporating reinduction with fludarabine, cytarabine, and amsacrine followed immediately by reduced-intensity allogenic transplantation yielded reasonable outcomes for a fraction of patients who had otherwise persistent disease. 19 However, novel approaches are still required. More effective yet less toxic conditioning regimens to deplete detectable residual tumor, 12, 25 enhanced immunologic surveillance of residual disease, 26 or post-transplantation maintenance therapy 27 all may be required to produce effective leukemia control for such high-risk patients.
In addition, measures of physiologic fitness to tolerate intensive conditioning and transplantation are needed. Patients may be particularly vulnerable to complications after extended but unsuccessful therapy to induce remission, along with its attendant period of extended neutropenia.
This will require careful patient selection, aggressive supportive-care techniques, and vigorous infection prophylaxis to identify the patients with active disease who are most likely to benefit from transplantation. Early referral and prompt donor identification remain essential to avoid delays that put patients at risk for early disease progression or relapse or clinical deterioration, further compromising post-HCT outcomes. Nonetheless, these data, even recognizing the limits of selection evident in a transplantation registry-based report, still demonstrate that inherent leukemic sensitivity and the achievement of CR2 by conventional or novel approaches still yields better and curative outcomes for a larger fraction of patients. Thus, if added therapy can attain remission without compromising HCT eligibility, then transplantation during remission remains a preferred goal.
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